Targeting miR-199a reduces fibrosis in hypertrophic cardiomyopathy

• Stanislovas S. Jankauskas,
• Fahimeh Varzideh,
• Urna Kansakar,
• Gaetano Santulli

Affiliations

Stanislovas S. Jankauskas

Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, Montefiore University Hospital, New York, NY 10461, USA

Fahimeh Varzideh

Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, Montefiore University Hospital, New York, NY 10461, USA

Urna Kansakar

Department of Molecular Pharmacology, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Aging Research, Albert Einstein College of Medicine, Montefiore University Hospital, New York, NY 10461, USA

Gaetano Santulli

Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, Montefiore University Hospital, New York, NY 10461, USA; Department of Molecular Pharmacology, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Aging Research, Albert Einstein College of Medicine, Montefiore University Hospital, New York, NY 10461, USA; Corresponding author at: 1300 Morris Park Avenue, 10461 New York, NY, USA.